DNA icon

Neuronal Ceroid Lipofuscinosis 3 (Batten Disease) via the CLN3 c.461-280_677+382 Deletion

Summary and Pricing

Test Method

Targeted Deletion Testing via PCR
Test Code Test Copy GenesTest CPT Code Gene CPT Codes Copy CPT Codes Base Price
CLN3 81479 81479 $350
Test Code Test Copy Genes Test CPT Code Gene CPT Codes Copy CPT Code Base Price
3739CLN381479 81479 $350 Order Options and Pricing

An additional 25% charge will be applied to STAT orders. STAT orders are prioritized throughout the testing process.

Turnaround Time

4 weeks on average for standard orders or 2 weeks on average for STAT orders.

Please note: Once the testing process begins, an Estimated Report Date (ERD) range will be displayed in the portal. This is the most accurate prediction of when your report will be complete and may differ from the average TAT published on our website. About 85% of our tests will be reported within or before the ERD range. We will notify you of significant delays or holds which will impact the ERD. Learn more about turnaround times here.


Genetic Counselors


  • Renee Bend, PhD

Clinical Features and Genetics

Clinical Features

The neuronal ceroid lipofuscinoses (NCLs) are inherited neurodegenerative lysosomal storage disorders caused by the accumulation of ceroid and lipofuscin in various cell types, mainly cells of the cerebral cortex, cerebellar cortex, and retina (Dyken et al. 1988; Williams and Mole 2012). Characteristic features at onset include clumsiness, deterioration of vision and psychomotor functions, and seizures and behavioral changes. Progression of clinical features results ultimately in total disability, blindness and premature death. Although NCL affects primarily children, age of onset of symptoms varies from infancy to adulthood. The incidence of NCL is variable and ranges from 1.3 to 7 per 100,000 (Mole and Williams 2013). However, it is more common in northern European populations, particularly Finland where the incidence may reach 1 in 12,500 individuals and a carrier frequency of 1 in 70 (Rider and Rider 1988; Vesa et al. 1995). NCLs are clinically and genetically heterogeneous. A nomenclature and classification based both on the age of onset of symptoms and the disease-causing gene has been recently developed, which groups NCLs into thirteen subtypes (CLN1-8, 10-14) (Williams and Mole 2012). The causative gene for the CLN9 phenotype has not been identified yet (Schulz et al. 2004). CLN3 disease, juvenile, also known as Batten Disease or Spielmeyer-Vogt Disease, is the most common neurodegenerative disorder of childhood (Zeman 1974). It is characterized by onset between 5-10 years of age, death in the third decade of life and mild features. Progressive visual loss is usually the first manifestation followed by seizures and cognitive and motor decline. Psychotic symptoms have also been reported (Adams et al. 2010).


Most CLNs, including CLN3, are inherited in an autosomal recessive manner. Thirteen genes have been implicated in CLNs: PPT1, TPP1, CLN3, CLN5, CLN6, MFSD8, CLN8, CTSD, DNAJC5, CTSF, ATP13A2, GRN, and KCTD7 (Mole and Williams 2013). CLN3 is caused by defects in the CLN3 gene (ICBD 1995). About 60 CLN3 pathogenic variants have been reported in various ethnic populations and include missense; nonsense; splicing; and small insertions and deletions. A 1-kb genomic deletion (c.461-280_677+382del), accounts for up to 85% of pathogenic variants in patients with CLN3 (Human Gene Mutation Database; Munroe et al. 1997). The great majority of CLN3 pathogenic variants are predicted to result in truncated proteins.

The CLN3 gene encodes a transmembrane protein that is hypothesized to be involved in membrane trafficking and several other cellular functions.

Clinical Sensitivity - Targeted Deletion

The genomic deletion of 1.02 kb in the CLN3 gene accounts for up to 85% of pathogenic variants in patients with CLN3 disease (Munroe et al. 1997). To date, only two other multi-exonic deletions were reported (Human Gene Mutation Database). They appear to be private or rare (Mole and Williams 2013).

Testing Strategy

A genomic deletion of 1.02 kb in the CLN3 gene accounts for up to 85% of pathogenic variants in patients with Batten disease, also known as CLN3. This deletion is described as c.461-280_677+382del; it includes exons 8 and 9 of the gene (Munroe et al. 1997). This test involves amplification of patient DNA with specific PCR primers that flank the c.461-280_677+382del deletion. Positive control samples from patients homozygous and heterozygous for the deletion are included in this test. A healthy non-carrier is included as a negative control.

Indications for Test

Candidates for this test are patients with a clinical diagnosis of CLN3 (Batten disease), and biological relatives of patients who are known to have the c.461-280_677+382 deletion in the CLN3 gene.


Official Gene Symbol OMIM ID
CLN3 607042
Inheritance Abbreviation
Autosomal Dominant AD
Autosomal Recessive AR
X-Linked XL
Mitochondrial MT


Name Inheritance OMIM ID
Ceroid Lipofuscinosis Neuronal 3 AR 204200

Related Test

Retinitis Pigmentosa Panel


  • Adams H.R. et al. 2010. Developmental Medicine and Child Neurology. 52: 637-43. PubMed ID: 20187884
  • Dyken P.R. 1988. American journal of medical genetics. Supplement. 5: 69-84. PubMed ID: 3146331
  • Human Gene Mutation Database (Bio-base).
  • Mole S.E., Williams R.E. 2013. Neuronal Ceroid-Lipofuscinoses. In: Pagon RA, Adam MP, Bird TD, Dolan CR, Fong C-T, and Stephens K, editors. GeneReviews™, Seattle (WA): University of Washington, Seattle. PubMed ID: 20301601
  • Munroe P.B. et al. 1997. American Journal of Human Genetics. 61: 310-6. PubMed ID: 9311735
  • Rider J.A., Rider D.L. 1988. American journal of medical genetics. Supplement. 5: 21-6. PubMed ID: 3146319
  • Schulz A. et al. 2004. Annals of neurology. 56: 342-50. PubMed ID: 15349861
  • The International Batten Disease Consortium (IBDC) 1995. Isolation of a novel gene underlying Batten disease, CLN3. Cell 82:949-57. PubMed ID: 7553855
  • Vesa J. et al. 1995. Nature. 376: 584-7. PubMed ID: 7637805
  • Williams R.E., Mole S.E. 2012. Neurology. 79: 183-91. PubMed ID: 22778232
  • Zeman W. 1974. Journal of Neuropathology and Experimental Neurology. 33: 1-12. PubMed ID: 4812323


Ordering Options

We offer several options when ordering sequencing tests. For more information on these options, see our Ordering Instructions page. To view available options, click on the Order Options button within the test description.

myPrevent - Online Ordering

  • The test can be added to your online orders in the Summary and Pricing section.
  • Once the test has been added log in to myPrevent to fill out an online requisition form.
  • PGnome sequencing panels can be ordered via the myPrevent portal only at this time.

Requisition Form

  • A completed requisition form must accompany all specimens.
  • Billing information along with specimen and shipping instructions are within the requisition form.
  • All testing must be ordered by a qualified healthcare provider.

For Requisition Forms, visit our Forms page

Specimen Types

Specimen Requirements and Shipping Details

loading Loading... ×


An error has occurred while calculating the price. Please try again or contact us for assistance.

View Ordering Instructions

1) Select Test Method (Platform)

1) Select Test Type

2) Select Additional Test Options

No Additional Test Options are available for this test.

Note: acceptable specimen types are whole blood and DNA from whole blood only.
Total Price: loading
Patient Prompt Pay Price: loading
A patient prompt pay discount is available if payment is made by the patient and received prior to the time of reporting.
Show Patient Prompt Pay Price
Copy Text to Clipboard